Otsuka (OTCMKTS:OTSKY) Shares Up 6.9% – Here’s What Happened

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY)’s stock price traded up 6.9% on Thursday. The stock traded as high as $38.5220 and last traded at $38.5220. Approximately 2,460 shares traded hands during trading, a decline of 94% from the average daily volume of 41,980 shares. The stock had previously closed at $36.05.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Otsuka from a “hold” rating to a “strong-buy” rating in a report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Otsuka Price Performance

The company has a current ratio of 2.21, a quick ratio of 1.65 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average of $37.32 and a 200 day moving average of $35.55. The firm has a market capitalization of $40.93 billion, a PE ratio of 15.30, a price-to-earnings-growth ratio of 2.64 and a beta of 0.09.

Otsuka (OTCMKTS:OTSKY) last posted its earnings results on Friday, July 31st. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.19. The firm had revenue of $4.41 billion during the quarter, compared to the consensus estimate of $3.95 billion. Otsuka had a net margin of 15.50% and a return on equity of 12.86%. Otsuka has set its FY 2026 guidance at 2.119-2.119 EPS. As a group, research analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 2.23 EPS for the current fiscal year.

Otsuka Company Profile

Otsuka Holdings Co, Ltd. is a Japan-based healthcare company that oversees the Otsuka Group’s pharmaceutical, nutraceutical and consumer health businesses. The company’s operations are primarily conducted through subsidiaries, including Otsuka Pharmaceutical Co, Ltd., which researches, develops, manufactures and markets prescription medicines, over-the-counter products and health-related foods.

Otsuka’s pharmaceutical activities focus on areas such as psychiatry, oncology, cardiovascular and renal medicine, and several other specialized therapeutic fields.